Christine Sullivan, CNM
Family · San Diego, CANPI 1265424121
Payments from drug & device makers
Across 43 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$250
- Amgen$75
- Boston Scientific$73
- Lilly USA, LLC$65
- Optinose US, Inc.$46
- Kowa Pharmaceuticals America, Inc.$45
- plus $385 from 15 others
What the payments were for
- Food & beverage$938100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $250 |
| Amgen | 3 | $75 |
| Boston Scientific | 2 | $73 |
| Lilly USA, LLC | 3 | $65 |
| Optinose US, Inc. | 2 | $46 |
| Kowa Pharmaceuticals America, Inc. | 2 | $45 |
| Novartis | 2 | $40 |
| Exact Sciences | 2 | $40 |
| GSK | 2 | $36 |
| Agile Therapeutics, Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 2 | $30 |
| Astellas Pharma US Inc | 1 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| AstraZeneca | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Pfizer | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$938 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 29 | $976 |
| Famotidine | 19 | $354 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $272 |
| Amlodipine Besylate | 20 | $164 |
| Azithromycin | 19 | $150 |
| Fluconazole | 11 | $142 |
| Levothyroxine Sodium | 14 | $138 |
| Lisinopril | 12 | $127 |
| Cephalexin | 13 | $113 |
| Prednisone | 23 | $89 |
| Hydrochlorothiazide | 13 | $81 |
| Losartan Potassium | 12 | $78 |
| Atorvastatin Calcium | 13 | $59 |
Paid to pharmacies, not to this prescriber.
Other family in San Diego
- Nancy GardettoSan Diego$394K
- Dawn MeyerSan Diego$270K
- Erin DwyerSan Diego$189K
- Lizaveta NikitsinaSan Diego$36K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.